CCMR Two: A Phase IIa, Randomised, Double-blind, Placebo-controlled Trial of the Ability of the Combination of Metformin and Clemastine to Promote Remyelination in People With Relapsing-remitting Multiple Sclerosis Already on Disease-modifying Therapy
Clinical trial NCT05131828 · COMPLETED
Trial details
- NCT number
- NCT05131828
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-03-08
- Primary completion
- 2025-03-31
- Enrollment
- 70
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.